MONTREAL, May 19, 2009 (GLOBE NEWSWIRE) -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track status to ENB-0040 for the treatment of hypophosphatasia (HPP). ENB-0040 is Enobia’s enzyme replacement therapy (ERT) for HPP, a rare, potentially life-threatening genetic bone disease for which there is no currently approved therapy.
